Eur Respir J 2009; 33: 1403–1414
DOI: 10.1183/09031936.00084608
Copyright©ERS Journals Ltd 2009

Erythropoietin inhibits respiratory epithelial cell apoptosis in a model of acute lung injury

R. MacRedmond, G.K. Singhera and D.R. Dorscheid

ABSTRACT: Fas-mediated apoptosis of the alveolar epithelium is important in the pathogenesis of acute respiratory distress syndrome. Erythropoietin (EPO) has cytoprotective properties in other organ systems, and is relatively deficient in critical illness. This study investigates a potential role for EPO in reducing apoptosis in a model of acute lung injury.

Apoptosis was induced in human alveolar epithelial (A549) cells or normal human bronchial epithelial (NHBE) cells by Fas activation with CH-11 Fas-crosslinking antibody or by co-culture with polymorphonuclear neutrophils in a transwell system. The effect of recombinant human (rh)EPO on apoptosis was measured by poly(ADP-ribose) polymerase cleavage and cell death detection assay. The specific EPO–EPO receptor (EPOR)-mediated effect was determined using an EPO-blocking antibody or EPOR small interfering RNA.

Expression of EPOR was demonstrated in A549, NHBE and normal human alveolar epithelium. Fas- and neutrophil-mediated apoptosis of A549 and NHBE cells was inhibited by rhEPO by a specific EPO–EPOR-mediated mechanism. This anti-apoptotic effect was associated with induction of a pro-apoptotic Bcl-xL/Bax ratio.

EPO has cytoprotective properties in respiratory epithelium in an *in vitro* model, which may indicate a potential therapeutic role in acute lung injury.

KEYWORDS: **Acute respiratory distress syndrome, critically ill, Fas/Fas-ligand, polymorphonuclear cells**

AFFILIATIONS
Providence Healthcare Heart and Lung Institute, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.

CORRESPONDENCE
R. MacRedmond
Critical Care Research Group
Room #166
1081 Burrard St
St Paul's Hospital
Vancouver
BC
Canada V6Z-1Y6
Fax: 1 6048068351
E-mail: rmacredmond@mrl.ubc.ca

Received:
June 04 2008
Accepted after revision:
December 21 2008

STATEMENT OF INTEREST
None declared.

European Respiratory Journal
Print ISSN 0903-1936
Online ISSN 1399-3003

Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a complex, devastating disease complicating acute inflammatory conditions including sepsis, trauma and pneumonia. Despite advances in supportive care, mortality remains high at 30–50% [1].

ARDS is characterised by neutrophilic inflammation and injury to the endothelium and epithelium. Activation of the vascular endothelium occurs rapidly in response to local or systemic inflammation, resulting in increased permeability, extravasation of protein-rich fluid and interstitial oedema, along with adherence and margination of neutrophils. Alveolar flooding results if microvascular and interstitial pressures are high. Intact alveolar epithelium allows active clearance of alveolar oedema by active sodium and chloride transport. Damage to the alveolar epithelium, however, results in disruption of normal epithelial fluid transport [2] along with reduced production and turnover of surfactant [3] and loss of the tight epithelial barrier, allowing flooding of the alveoli with high molecular weight proteins and fluid. The degree of epithelial damage in ARDS is predictive of outcome [4].

Studies of humans and animals point to apoptosis as an important mechanism of epithelial cell death in ARDS. Histopathological changes of apoptosis have been demonstrated in both early and fatal ARDS in humans [5, 6], and in animal models of lipopolysaccharide (LPS)-induced ALI [7, 8]. Apoptosis occurs in response to activation of specific cell membrane receptors, termed ''death receptors'', of which the Fas receptor (CD95) is the best characterised. Several lines of evidence point to the importance of Fas/Fas-ligand (FasL) signalling in ALI. Soluble FasL (sFasL) is found in the bronchoalveolar lavage fluid of patients with ARDS, where levels correlate with the severity of disease [9], while Fas and FasL expression and co-localisation in alveolar epithelial cells has been shown in *post mortem* specimens from patients who died of ARDS [10]. In animal models, administration of

inhaled agonist anti-Fas antibody Jo-2 induces alveolar cell apoptosis and other pathological changes of ALI [11, 12]. LPS-induced lung injury in mice is associated with increased epithelial cell expression of Fas and infiltration of FasL-expressing inflammatory cells [8], while mice with mutations of Fas or FasL, or those treated with antagonist anti-Fas antibody, are protected against LPS-induced ALI [8, 13].

Erythropoietin (EPO) is a 30.4 kDa glycoprotein, which by activation of the EPO receptor (EPOR) is the critical modulator of erythroid production in response to anaemia [14]. The stimulus for EPO production and EPOR expression is not red cell mass, however, but rather tissue oxygen supply *via* upregulation of the hypoxia-inducible factor-1α. The kidney is the major site of production and secretion of EPO; however, EPO secretion has also been demonstrated in diverse tissues including nervous, vascular, liver, intestinal epithelium and reproductive organs [14]. This wide distribution of EPO and EPOR expression has stimulated great interest in the other biological roles of EPO, particularly with regard to cytoprotection.

EPO confers cytoprotection by a number of pathways involving Janus kinase-2 signalling, including upregulation of anti-apoptotic genes such as Bcl-xL and Bcl-2 [15] and inactivation of pro-apoptotic caspase-9 and Bad [16]. The cytoprotective properties of EPO have been demonstrated in numerous models of ischaemic and inflammatory injury, largely in neuronal, vascular and cardiac tissues [17]. Little is known regarding expression or function of EPO/EPOR in pulmonary tissues or the potential role of EPO in pathological processes in the lung.

In this study we demonstrate, for the first time, expression of EPO and its receptor in respiratory epithelial cells. Using a cell-culture model of ALI, we show anti-apoptotic activity of recombinant human (rh)EPO in Fas- and neutrophil-mediated epithelial cell apoptosis, and that this effect is mediated by specific EPO–EPOR interactions. We propose induction of an anti-apoptotic Bcl-xL/Bax phenotype as a mechanism of the observed cytoprotective effect. Administration of rhEPO may thus represent a potential therapy for ARDS if additional studies confirm its protective role in animal models of ALI.

MATERIALS AND METHODS

Reagents

Recombinant human interferon (IFN)-γ (#285-IF) and anti-EPO neutralising antibody (MAB287) were purchased from R&D Systems Inc. (Minneapolis, MN, USA). Anti-human Bcl-xL (#sc-1413), anti-human EPO (#SC-7956) and anti-human EPOR (#sc-697) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Anti-human Bax (#554104) was purchased from BD Pharmingen (Mississauga, ON, Canada). β-actin monoclonal antibody (mAb; #AC-74) and *Escherichia coli* LPS (L4391) were purchased from Sigma Aldrich (Oakville, ON, Canada). Poly(ADP-ribose) polymerase (PARP) mouse mAb (clone C-2-10) was purchased from Biomol Research Labs (Plymouth Meeting, PA, USA) and anti-Fas mAb (clone CH-11) from MBL International (Woburn, MA, USA). EPOR small interfering (si)RNA (Hs_EPOR_5 HP Validated siRNA (NM_000121)) was purchased from Qiagen (Mississauga).

Cell lines and culture

Human alveolar epithelial (A549) cells (European Collection of Cell Cultures, Porton Down, UK) were cultured at 37°C in 5% CO_2 in Ham's F12 (Gibco-BRL, Carlsbad, CA, USA), 10% fetal calf serum (FCS), 1% penicillin/streptomycin. Normal human bronchial epithelial (NHBE) cells were isolated and cultured as described by GRAY *et al.* [18]. Bronchi were obtained from patients undergoing lung resection due to lung cancer or benign lung tumours. The Ethics Committee of Providence Healthcare (Vancouver, BC, Canada) approved the study and all patients provided informed consent to participate in the investigation. Prior to agonist treatment, cells were washed with serum-free F12 and placed under serum-free conditions or in medium containing 1% FCS for LPS stimulations.

Real-time PCR

mRNA was quantified using commercially available SYBR Green assays (Qiagen). The results are expressed as the ratio of the mean of triplicate target gene cDNA measurements to the triplicate housekeeping gene (β-actin) measurement. Primers used were as follows: Bcl-xL forward 5′-GAT GCA CAT AGC GTT CCC CT-3′, reverse 5′-CCC TAG CAG ATA AAG TGA CGG G-3′; Bax forward 5′-GGT TTC ATC CAG GAT CGA GCA GG-3′, reverse 5′-ACA AAG ATG GTC ACG GTC TGC C-3′; β-actin forward 5′-TGG AGA AGA GCT ATG AGC TGC CTG-3′, reverse 5′-GTG CCA GAC AGC ACT GTG TTG-3′; EPO forward 5′-GCC AGA GGA ACT GTC GAG AG-3′, reverse 5′-ATG GTA GGT GCC AAA ACA GG-3′; and EPOR forward 5′-GAG CAT GCC CAG GAT ACC TA-3′, reverse 5′-TAC TCA AAG CTG GCA GCA GA-3′.

Flow cytometry

Flow cytometric analyses were performed as described previously [19], by standard techniques using murine immunoglobulin (Ig)G isotype controls (BD Pharmingen) and specific anti-Fas (clones ZB4; PanVera, Madison, WI, USA) as primary antibodies.

Cell death detection ELISA

Apoptosis was demonstrated in treated A549 or NHBE cells utilising the ELISA kit from Roche Applied Science (#1774425; Mannheim, Germany). This technique uses mouse mAbs directed against DNA and histones. This allows the specific determination of mono- and oligonucleosomes in the cytoplasmic fractions of cell lysates [20, 21].

Western blot

Protein was collected from total cell lysates and western blots were performed as previously described [22]. Nitrocellulose membranes were stripped and reprobed for β-actin to normalise differences in protein loading. Densitometry was performed on autoradiographs to quantitate expression, and normalised to β-actin protein expression.

Immunohistochemistry

Ethics approval for the use of human tissues was granted by the St Paul's Hospital Ethics Review Board (Vancouver, BC, Canada). Paraffin-embedded sections of normal lung parenchyma from patients undergoing lung resection were obtained from the Tissue Registry (iCAPTURE Centre, Vancouver). Slides were processed with standard techniques of Citra

buffer heat-induced antigen retrieval procedure (Dako, Mississauga), Following blocking, slides were incubated in primary antibody (rabbit anti-EPOR 1:50 or rabbit IgG isotype control 1:200) overnight at 4°C and immunostained as previously described [23].

Transfection and siRNA

Cells were transfected with Hs EPOR_5 HP Validated siRNA (NM_000121) or scramble (Scr) siRNA (Qiagen) using the HiPerfect transfection reagent (Qiagen) in 24-well plates according to the manufacturer's instructions and using standard optimisation procedures. After incubation in transfection medium for 24 h, medium containing the transfection reagent was discarded, and the cells were maintained in fresh medium for another 24 h prior to stimulation with IFN-γ, CH-11 and rhEPO as indicated.

Isolation of polymorphonuclear neutrophils

Polymorphonuclear neutrophils (PMNs) were isolated from blood drawn from healthy control subjects using standard methodology of Hypaque-Ficoll density-gradient centrifugation, dextran sedimentation and hypotonic lysis of erythrocytes [24]. PMNs were maintained in Iscove's modified Dulbecco's medium. Purity and viability were confirmed by May-Grunwald-Giemsa (Sigma Aldrich) and Trypan Blue (Sigma Aldrich) staining, respectively.

Statistical analysis

Data were analysed with GraphPad Prism 3.0 software package (GraphPad Software, San Diego, CA, USA). Values are presented as mean±SEM. The significance of differences between means was assessed by unpaired t-tests. Multiple groups were compared by one-way ANOVA and by Bonferoni's *post hoc* t-test. A p-value <0.05 was considered significant.

RESULTS

Respiratory epithelial cells expressed EPO and EPOR

Gene and protein expression of EPO was demonstrated in A549 cells and was downregulated by LPS at 24 h (fig. 1a–c). EPO expression was not found in NHBE cells (data not shown). EPOR mRNA and protein were expressed in A549 (fig. 1d–f) and primary NHBE cells (fig. 1g–i), and expression was not regulated by LPS. EPOR expression was also demonstrated in normal human alveolar epithelial cells by immunohistochemistry (fig. 1j and k); however, EPO expression was not seen (data not shown).

Fas-mediated apoptosis of A549 cells was inhibited by rhEPO

A549 cells have previously been shown to be resistant to Fas-mediated apoptosis due to failure to express Fas receptor on the cell membrane. Susceptibility to Fas-mediated apoptosis by CH-11 anti-Fas agonist antibody is incurred following upregulation of surface Fas expression by IFN-γ [10]. This result was reproduced in the present study. There was no membrane expression of Fas above isotype control in unstimulated A549 cells, as demonstrated by flow cytometric analysis, and surface expression was induced following incubation with IFN-γ (fig. 2a). Using cleavage of PARP and detection of the p85 cleavage product as a marker of apoptosis (fig. 2b), it was found that apoptosis was induced in a dose-dependent fashion by incubation with IFN-γ and CH-11 in combination (lanes 4 and 5) but not by either stimulus used alone (lanes 2 and 3). Co-incubation with rhEPO completely abrogated this effect (lane 6). Semiquantitative analysis of the effect by densitometry demonstrated significant inhibition of PARP cleavage by EPO (fig. 2c). We went on to quantify this effect by measurement of free nucleosome release into the supernatant (fig. 2d). Free nucleosome release was significantly increased by IFN-γ and CH-11, and there was a dose-dependent inhibition of this effect by co-incubation with rhEPO.

EPO mediated anti-apoptotic effect in A549 cells by specific EPO–EPOR interaction

Two complementary methods were used to confirm that the observed cytoprotective effect was mediated by specific EPO/EPOR signalling. First, expression of EPOR was knocked down by transfection of A549 cells with EPOR siRNA (Hs_EPOR_5 HP Validated siRNA (NM_000121)). Confirmation of transfection efficiency is demonstrated in figure 3a, with the highest dose of EPOR siRNA (100 nM) achieving ~70% reduction in EPOR expression compared with control-transfected cells. rhEPO continued to exert an anti-apoptotic effect following transfection of Scr siRNA or EPOR siRNA (50 nM), with significant reduction in free nucleosome release compared with CH-11 and IFN-γ alone. This anti-apoptotic effect of rhEPO was lost following transfection of the higher dose of EPOR siRNA (100 nM), with no significant reduction in free nucleosome release compared with CH-11+IFN-γ-treated cells (fig. 3b). EPOR siRNA (100 nM)-transfected cells underwent significantly more CH-11-induced apoptosis than Scr siRNA-transfected cells in the presence of rhEPO (fig. 3b). Secondly, experiments were repeated following pre-treatment with the anti-EPO neutralising antibody MAB287 (R&D Systems Inc.) [25] at 5 $\mu g \cdot mL^{-1}$ (fig. 3c). The anti-apoptotic effect of rhEPO was completely abrogated by co-incubation with this EPO-neutralising antibody.

EPO upregulated Bcl-xL/Bax expression ratio in the presence of LPS

The balance of anti-apoptotic Bcl proteins, such as Bcl-xL, to pro-apoptotic proteins, such as Bax, is an important determinant of mitochondrial membrane integrity, preventing cytochrome c release into the cytosol where it forms the apoptosome. We next looked at gene and protein expression of Bcl-xL relative to Bax as a potential mechanism of our observed anti-apoptotic effect (fig. 4). As ALI often occurs in the setting of severe sepsis, we were interested to determine if this effect would be maintained in the setting of endotoxin/LPS, a critical determinant of Gram-negative sepsis. Incubation of A549 cells with rhEPO (1 $unit \cdot mL^{-1}$) or LPS (1 $\mu g \cdot mL^{-1}$), alone or in combination, for 24 h, resulted in significant upregulation of Bcl-xL/Bax mRNA relative to control. LPS and EPO treatment alone resulted in a trend towards increased Bcl-xL/Bax protein ($p=0.09$ in each case), while co-incubation with LPS and EPO caused a significant increase in the anti-apoptotic Bcl-xL/Bax protein ratio. When we looked at the relative contribution of Bcl-xL and Bax modulation to this effect, there was no significant effect of EPO or LPS alone or in combination on the expression of either molecule, although the effect appeared to be driven primarily *via* upregulation of



FIGURE 1. Respiratory epithelial cells express erythropoietin (EPO) and the EPO receptor (EPOR). Human alveolar epithelial (A549) cells or normal human bronchial epithelial (NHBE) cells were grown to confluence in 6-well plates. Cells were washed, placed in low serum (1% fetal calf serum) medium and left untreated or incubated with lipopolysaccharide (LPS; $1 \mu g \cdot mL^{-1}$) for 24 h. Total RNA or protein was extracted for real-time PCR and western blot analysis. a, d and g) Gene and b, e and h) protein expression relative to β-actin, plus c, f and i) representative western blot images of a–c) EPO and d–f) EPOR in A549 cells and g–i) EPOR in NHBE cells. NHBE cells did not express EPO mRNA or protein. Representative images of immunohistochemical expression of j) EPOR and k) isotype control in normal human alveolar tissue. Positive staining is pink with New Fuschin substrate. Insets show normal alveolar ultrastructure. All experiments were performed a minimum of three times. Values are expressed as mean±SE. Scale bars=10 μm. *: $p<0.05$.



FIGURE 2. Erythropoietin (EPO) inhibited Fas-mediated apoptosis in human alveolar epithelial (A549) cells. a) A549 cells were incubated with interferon (IFN)-γ (250 units·mL^{-1}) for 24 h. Cells were then trypsinised, washed and labelled with an isotype control (red line) or anti-Fas monoclonal antibody (black line: unstimulated cells; blue line: IFN-γ-treated cells) and fluorophore-conjugated detection antibodies. Fas expression was quantified by flow cytometry and the graph is representative of three independent experiments. b and c) A549 cells were incubated with Fas-activating CH-11 antibody (0.1 or 1 μg·mL^{-1}) and IFN-γ (250 units·mL^{-1}), alone and in combination, with or without recombinant human (rh)EPO (1 unit·mL^{-1}), for 24 h. Apoptosis was determined by p85 poly(ADP-ribose) polymerase (PARP) expression in total cell lysates by western blot. b) The blot is representative of three independent experiments. c) Densitometric analysis of p85 PARP expression. d) A549 cells were stimulated with IFN-γ and CH-11 (1 μg·mL^{-1}), with or without rhEPO (0.1 or 1 unit·mL^{-1}), and apoptosis was measured by free nucleosome release into the supernatant using cell death detection ELISA. Data are expressed as mean±SE and were obtained from three experiments. *: $p<0.05$.

Bcl-xL, which was increased 1.8 times above control by EPO and LPS in combination (p=0.07).

EPO was anti-apoptotic in primary respiratory epithelial cells

Although widely used in the study of respiratory epithelial cell biology, A549 cells are an immortalised cell line and, as such, apoptotic responses cannot be predictably assumed to translate into primary tissues. We therefore went on to confirm our findings in primary NHBE cells. NHBE cells express Fas on their surface (fig. 5a) and therefore did not require IFN-γ for induction of apoptosis by CH-11. Incubation of NHBE cells with CH-11 resulted in significant increase in free nucleosome release, which was inhibited in a dose-dependent fashion by co-incubation with rhEPO. Apoptosis was completely abrogated with the higher dose of EPO (fig. 5b). In the presence of LPS, apoptosis was also inhibited but remained significantly increased above control even with the high dose of EPO (fig. 5c). The apoptosis and cytoprotective effect of EPO was further demonstrated by p85 PARP cleavage (fig. 5d), which was associated with a concordant reduction in Bcl-xL/Bax protein expression in response to CH-11 (fig. 5e), and restoration to control levels by rhEPO. We went on to examine the specific effects on Bcl-xL and Bax expression. In contrast to the effects with LPS, the predominant effect of EPO in the setting of Fas activation was seen on Bax expression (fig. 5f), with significant upregulation of Bax in response to CH-11 and abrogation of the effect by co-incubation with rhEPO. Bcl-xL expression remained stable under these conditions (fig. 5g).

EPO protected epithelial cells from neutrophil-mediated apoptosis

In order to expand our hypothesis in a more physiologically relevant model pertinent to ARDS, we went on to examine the cytoprotective effect of EPO in a co-culture model of alveolar epithelial cells with PMNs. Co-incubation of A549 cells with



FIGURE 3. Erythropoietin (EPO) inhibited apoptosis in human alveolar epithelial (A549) cells by specific EPO–EPO receptor (EPOR) interaction. a) A549 cells were transfected with EPOR small interfering (si)RNA (Hs_EPOR_5 HP Validated siRNA (NM_000121)), using standard techniques for transfection and optimisation. Total protein lysates were collected and densitometric analysis of EPOR/β-actin expression by western blot was performed. b) A549 cells were transfected with EPOR siRNA (■: 50 nM; ■: 100 nM) or scramble (Scr) siRNA (■) prior to incubation with interferon (IFN)-γ and CH-11 antibody (1 μg·mL^{-1}) with or without recombinant human (rh)EPO (0.1 or 1 unit·mL^{-1}) for 24 h. □: control. c) A549 cells were pre-treated with the anti-EPO neutralising antibody MAB287 (▨; 5 μg·mL^{-1}) for 30 min prior to incubation with CH-11 (1 μg·mL^{1}) with or without rhEPO (0.1 or 1 unit·mL^{-1}) for 24 h. Apoptosis was quantified by cell death detection ELISA. Data are expressed as mean±SE and were obtained from three experiments. *: $p<0.05$; #: $p<0.05$ *versus* match-transfected CH-11+IFN-γ-treated cells.

PMNs in a transwell system to prevent direct cell–cell contact resulted in apoptosis as demonstrated by PARP cleavage, with a dose-dependent inhibition of apoptosis by rhEPO (fig. 6a). Again, apoptosis was associated with a concordant significant downregulation of Bcl-xL/Bax protein expression, which was inhibited by co-incubation with rhEPO (fig. 6b).

DISCUSSION

ARDS is a severe and frequently fatal condition complicating critical illness of many aetiologies. Apoptotic injury to the type 2 pneumocytes is an important component of the pathophysiology of ARDS and a critical determinant of outcome, while Fas/FasL signalling has been implicated in death signalling in this disease. Current therapy in ARDS consists of supportive care and treatment of the underlying cause, while therapies directed against the inflammatory processes have been unsuccessful in clinical trials [26]. Failure of these therapies probably reflects the complexity and redundancy of the systemic inflammatory response, but also the importance of apoptosis, which is not targeted by these agents. In the current study, we have shown, for the first time, expression of EPO and its receptor in respiratory epithelium. We demonstrated a cytoprotective effect of rhEPO in cultured alveolar and bronchial epithelial cells in models of Fas- and neutrophil-mediated apoptosis, which was mediated by specific EPO–EPOR interactions. This effect was mediated, at least in part, by induction of an anti-apoptotic Bcl-xL/Bax phenotype.

Expression of EPO and EPOR has been demonstrated in a wide variety of tissues, and recent years have seen an explosion in interest in the anti-apoptotic properties of EPO in a variety of conditions, particularly with respect to ischaemia/reperfusion injury to neuronal and cardiac tissue [17]. While expression of EPO and EPOR has previously been reported in nonsmall cell lung cancer [27] and fetal lung [28], this is the first time that expression has been demonstrated in normal human lung tissues.

Anaemia of chronic disease occurs in the setting of persistent acute or chronic immune activation [29] and has multiple causes, including inhibition of EPO production and responsiveness. Consistent with reduced EPO production in LPS-treated rats [30], the present study found downregulation of EPO gene and protein expression following LPS treatment in A549 cells. Potential mechanisms include inhibition of EPO gene expression by the transcription factor nuclear factor (NF)-κB [31], which is upregulated by LPS, or a secondary effect through induction of pro-inflammatory cytokines including interleukin-1β and tumour necrosis factor-α, which have also been shown to inhibit EPO gene and protein expression [32]. Importantly, EPOR expression was not significantly altered in the epithelium by LPS in our model, permitting a robust cytoprotective effect of EPO under conditions of LPS stimulation. We were unable to detect EPO gene or protein expression in primary bronchial epithelial cells or in alveolar epithelial tissue, suggesting that local production of EPO, at least by the epithelium, is less important than circulating levels in critical illness. Whether other resident cells of the lung, including the alveolar macrophages, are a physiologically relevant source of EPO in ALI has not been determined, although we have demonstrated expression of both EPO and EPOR in alveolar macrophages *ex vivo* (data not shown). EPO expression was not



FIGURE 4. Erythropoietin (EPO) induced an anti-apoptotic Bcl-xL/Bax phenotype in human alveolar epithelial (A549) cells. A549 cells were grown to confluence in 6-well plates and incubated with lipopolysaccharide (LPS; 1 μg·mL^{-1}) and recombinant human (rh)EPO (1 unit·mL^{-1}), alone or in combination. a) Ratio of Bcl-xL/Bax mRNA expression quantified by real-time PCR. Densitometric analysis of b) Bcl-xL/Bax, c) Bcl-xL/β-actin and d) Bax/β-actin protein expression by western blot of total protein lysates. e) Representative western blot of Bcl-xL, Bax and β-actin protein expression in A549 cells. Data are expressed as mean±SE and were obtained from six experiments. *: $p<0.05$ *versus* control.

demonstrated by immunohistochemistry in the vascular endothelium in our lung sections; however, induced expression of EPO has previously been demonstrated in vascular endothelium in a model of compressive spinal injury [33].

Inhibition of the EPO–EPOR interaction by gene silencing of EPOR by siRNA or by incubation with EPO-neutralising antibody inhibited the cytoprotective effect of rhEPO in our model. Although not statistically significant, there was a trend towards residual anti-apoptotic effect even with EPOR siRNA at 100 nM. We were unable to completely knock down EPOR expression, and the trend towards the cytoprotective effect probably represents signalling through the remaining 20–30% expressed receptor. EPOR-independent EPO signalling has not been described in the literature to date, and while such an effect cannot be discounted based on our data, it is less likely to be the mechanism of the residual effect.

Numerous human studies have implicated Fas-induced apoptosis in the pathogenesis of ARDS [8, 10, 34], while the inflammatory and apoptotic changes of ARDS are induced in animal models by both human sFasL and by the Fas-activating antibody Jo-1 [12, 35]. Following induction of membrane Fas expression in A549 cells, apoptosis was induced by cross-linkage and activation of Fas by CH-11 antibody. Lack of Fas expression by A549 cells is probably a characteristic of the tumour origin of these cells as a mechanism of immune resistance, rather than a characteristic of alveolar epithelial cells. Fas expression has been demonstrated in alveolar epithelial cells of patients who died of ARDS [10], and in primary distal lung epithelial cells in culture [36]. Consistent with previous data [36], NHBE cells expressed Fas on the membrane and apoptosis was induced by Fas ligation in the current study.

LPS induces alveolar epithelial cell apoptosis in whole-animal models of ARDS [7]; however, in our hands, A549 cells were



FIGURE 5. Erythropoietin (EPO) abrogated Fas-mediated apoptosis in normal human bronchial epithelial (NHBE) cells. a) NHBE cells were trypsinised, washed and labelled with an isotype control (——) or anti-Fas monoclonal (- - -) antibody and fluorophore-conjugated detection antibodies. Fas expression was quantified by flow cytometry and the graph is representative of three independent experiments. b and c) NHBE cells were seeded on 24-well plates and stimulated with CH-11 antibody (1 $\mu g \cdot mL^{-1}$) with or without recombinant human (rh)EPO (0.1 or 1 unit·mL^{-1}) for 24 h, b) without and c) with LPS (1 $\mu g \cdot mL^{-1}$), and apoptosis was quantified by cell death detection ELISA. d–g) NHBE cells were grown to confluence in 12-well plates. Cells were washed and placed in low serum (1% fetal calf serum) medium and incubated with CH-11 (1 $\mu g \cdot mL^{-1}$) with or without rhEPO (0.1 or 1 unit·mL^{-1}) for 24 h. Total protein lysates were collected and western blot analysis of d) p85 poly(ADP-ribose) polymerase (PARP) relative to β-actin, e) Bcl-xL/Bax ratio, and f) Bax and g) Bcl-xL protein expression relative to β-actin was performed. h) Representative western blots of Bcl-xL, Bax and β-actin protein expression in NHBE cells. Data are expressed as mean±SE and were obtained from a minimum of three experiments. *: $p<0.05$ *versus* control; #: $p<0.05$ *versus* CH-11 alone.

resistant to induction of apoptosis by LPS, even at high doses up to 10 $\mu g \cdot mL^{-1}$ (data not shown). Apoptosis in cultured A549 cells [37] and tracheobronchial epithelial cells [38] treated with LPS has been reported only with very high doses of LPS (100 $\mu g \cdot mL^{-1}$), which are of questionable clinical significance. LPS-induced apoptosis *in vivo* probably is the result of more complex convergence of death signals, including the Fas/FasL pathway [8]. A549 cells treated with LPS tended towards an



FIGURE 6. Erythropoietin (EPO) abrogated neutrophil-mediated apoptosis of human alveolar epithelial (A549) cells. Polymorphonuclear neutrophils (PMNs) were isolated from healthy volunteers by Hypaque-Ficoll density-gradient separation as described. A549 cells were grown to confluence in 6-well plates, washed and placed in low serum (1% fetal calf serum) medium with or without recombinant human (rh)EPO (0.1 or 1 unit·mL^{-1}). PMNs (2.5×10^5) were placed in the upper chamber of transwell polycarbonate microporous inserts (0.3 μm membrane) above the epithelial cell monolayer. Total protein lysates were collected from the epithelial layer after 24 h. Densitometric analysis of western blot determination of a) p85 poly(ADP-ribose) polymerase (PARP) and b) Bcl-xL/Bax protein expression. Data are expressed as mean±SE and were obtained from a minimum of three experiments. *: $p<0.05$ *versus* control; **: $p<0.01$ *versus* control; $^{\#}$: $p<0.05$ *versus* PMN alone; $^{\#\#}$: $p<0.01$ *versus* PMN alone.

anti-apoptotic phenotype. Similar to the observation of LPS-mediated upregulation of Bcl-xL mRNA in murine hepatocytes [39], LPS resulted in upregulation of Bcl-xL/Bax mRNA in A549 cells, although no significant change in protein expression was observed. Co-incubation with rhEPO significantly promoted an anti-apoptotic Bcl-xL/Bax phenotype in A549 cells in the presence of LPS, which may be protective in a more complex model where multiple apoptotic signals are in effect. In NHBE cells, Fas-mediated apoptosis was completely abrogated by rhEPO, and this anti-apoptotic effect was maintained in the presence of LPS. This is important in the clinical context of sepsis as a major pathogenic determinant of ARDS.

Apoptosis is tightly regulated by the balance of a number of anti- and pro-apoptotic molecules, including Bcl-xL and Bax, both of which can be modulated by EPO. Fas activation can result in caspase-dependent (type I) apoptosis or mitochondrial-dependent (type II) apoptosis [40]. Type II apoptosis is regulated by members of the the Bcl-2 family. The pro-apoptotic proteins Bax and Bak induce cell death by oligomerisation and translocation to the mitochondrial membrane, resulting in mitochondrial membrane permeabilisation, an effect which is inhibited by anti-apoptotic members such as Bcl-xL and Bcl-2 [41]. Phosphatidylinositol-3-kinase/Akt-mediated upregulation of Bcl-xL has been implicated in EPO-mediated cytoprotection in endothelial cells [42], while downregulation of Bax by rhEPO has been shown in models of ischaemia in the kidney and brain [43, 44]. In the present study, we demonstrated similar effects in respiratory epithelial cells. In the presence of LPS, the effect of EPO was observed predominantly through upregulation of Bcl-xL. We saw no change in EPOR expression in A549 or NHBE cells with LPS treatment, indicating an effect downstream of the EPOR. Bcl-xL gene transcription is regulated by NF-κB, which is a downstream target of both EPOR and the LPS receptor Toll-like receptor-4, and is a potential mediator of the synergistic effect of LPS and EPO. In contrast, our data indicate that Fas-mediated apoptosis of respiratory epithelium is associated with upregulation of Bax. This suggests that activation of the mitochondrial intrinsic apoptotic pathway is important in Fas-mediated apoptosis of the respiratory epithelium, although additional anti-apoptotic mechanisms involving type I apoptosis cannot be discounted. In the context of Fas-mediated apoptosis, downreguation of Bax appears to be the more important mechanism of EPO-mediated cytoprotection, although additional effects *via* Bcl-xL regulation may be important in the presence of LPS.

Continuing this concept of a more complex model of apoptotic injury, we went on to examine the effect of rhEPO in a model of neutrophil-mediated apoptosis. Animal models show movement of neutrophils through epithelium and endothelial membranes without damage or degranulation [45], while in a rabbit model of streptococcal-induced lung inflammation, the major metabolic activity of neutrophils occurred in the alveolar space rather than the interstitium or microvasculature [46]. These data suggest that indirect mediator effects may be more important than direct cell–cell interactions in neutrophil-induced apoptosis in ALI, and sFasL is a candidate mediator [8, 10].

The current study adopted the model of SERRAO *et al.* [47], who demonstrated that apoptosis of A549 cells in transwell co-culture was mediated by sFasL. Consistent with their data, apoptosis was induced in A549 cells by co-culture with PMNs isolated from healthy volunteers. A recent study reported apoptosis of distal lung epithelial cells induced by neutrophil elastase (NE) [48]; however, in our hands, A549 cells were resistant to induction of apoptosis by NE (data not shown), suggesting that this was not a mechanism here. Abrogation of apoptosis by rhEPO was again associated with a concordant modulation of Bcl-xL/Bax expression. sFasL was measurable in the supernatant by ELISA and levels were not altered by EPO (data not shown), indicating that inhibition of sFasL release was not responsible for the cytoprotective effect in this model.

Taken together, our data suggest that, in the context of sepsis-induced ALI, EPO has potential for complementary mechanisms of cytoprotection, the net result of which includes induction of an anti-apoptotic Bcl-xL/Bax phenotype in the epithelium. Our data is, however, limited to association and does not define regulation of Bcl-xL/Bax as the only mechanism of cytoprotection in our model. While EPO mediated a consistent anti-apoptotic effect in different respiratory epithelial cell types under different conditions, with concordant increase in Bcl-xL/Bax ratio, the individual effects on Bcl-xL and Bax expression were inconsistent and, at times, small. The protective effects of EPO in respiratory epithelium thus almost certainly include additional as yet undefined mechanisms. Candidate mechanisms implicated in other organ systems include regulation of other Bcl-2 family proteins [49], apoptotic protease-activating factor-1 and caspase expression and activity [50].

ARDS is characterised by severe tissue and alveolar hypoxaemia, where microcirculatory dysfunction in sepsis contributes to the local tissue hypoxia. One would expect, therefore, that EPO and EPOR levels would be high. Critical illness, however, is characterised by decreased EPO production, decreased bone marrow response to EPO and reduced red blood cell survival [51–53]. This, combined with the association of blood transfusion with poorer outcome, led to a number of studies investigating the use of EPO in critically ill patients to reduce transfusion requirements. A recently published multicentre randomised controlled trial [54] found no reduction in red cell transfusion with use of EPO, possibly reflecting the adoption of more conservative transfusion thresholds. However a reduction in mortality in a pre-specified subgroup analysis of trauma patients hints at a clinically relevant cytoprotective effect. The rate of thrombotic vascular events in the EPO group was increased compared with the placebo group, and was increased depending on the number of doses, although this increased thrombotic risk was not seen in patients also receiving heparin prophylaxis.

While many therapies are in development that are aimed at various components of the apoptotic cascade, including caspase inhibitors, death receptor antagonists and Bcl-2 family modulators, none have yet reached clinical use [55]. Recombinant human EPO has a long history of safety and efficacy in treating anaemia in chronic renal disease, while recent reports regarding reduced survival in cancer patients [56] are unsurprising given what is now known regarding EPOR expression in tumour cells [57] and the cytoprotective effect of EPO. A number of phase II trials have demonstrated safety and efficacy of rhEPO and darbopoietin in acute stroke and myocardial infarction [58, 59], achieving serum concentrations in the range of 5 units·mL^{-1} with no increase in thrombotic events. Care must be taken in extrapolating this safety data to a critical care population. Our data demonstrating a cytoprotective effect in respiratory epithelial cells represent a novel therapeutic opportunity for EPO in critical illness as a cytoprotective agent in ARDS. It is likely that the doses required to achieve such an effect will be higher and/or more frequent than those employed in trials aimed at the haematopoietic properties of EPO in critical illness, with potential increased risk of thrombosis. Whether this risk can be offset by the co-administration of anti-coagulants such as heparin, as in the trial by CORWIN *et al.* [54], or by the use of newer rhEPO analogues would require vigorous safety evaluation.

Critical illness involves a dysregulated EPO response to global and microvascular hypoxia, and loss of the cytoprotective effect may contribute to the apoptotic alveolar epithelial injury of ARDS. This study shows the potential for protecting respiratory epithelial cells from apoptosis with exogenously administered EPO, demonstrating an important pathway in the lung epithelium that may be exploited for therapeutic use in the future. Further *in vivo* studies will be required to confirm these effects and to determine optimal timing and duration of therapy.

REFERENCES

1 Ware LB, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med* 2000; 342: 1334–1349.

2 Matthay MA, Flori HR, Conner ER, *et al.* Alveolar epithelial fluid transport: basic mechanisms and clinical relevance. *Proc Assoc Am Physicians* 1998; 110: 496–505.

3 Greene KE, Wright JR, Steinberg KP, *et al.* Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. *Am J Respir Crit Care Med* 1999; 160: 1843–1850.

4 Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2001; 163: 1376–1383.

5 Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. *Clin Chest Med* 1982; 3: 35–56.

6 Bardales RH, Xie SS, Schaefer RF, *et al.* Apoptosis is a major pathway responsible for the resolution of type II pneumocytes in acute lung injury. *Am J Pathol* 1996; 149: 845–852.

7 Vernooy JH, Dentener MA, van Suylen RJ, *et al.* Intratracheal instillation of lipopolysaccharide in mice induces apoptosis in bronchial epithelial cells: no role for tumor necrosis factor-α and infiltrating neutrophils. *Am J Respir Cell Mol Biol* 2001; 24: 569–576.

8 Kitamura Y, Hashimoto S, Mizuta N, *et al.* Fas/FasL-dependent apoptosis of alveolar cells after lipopolysaccharide-induced lung injury in mice. *Am J Respir Crit Care Med* 2001; 163: 762–769.

9 Matute-Bello G, Liles WC, Steinberg KP, *et al.* Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS). *J Immunol* 1999; 163: 2217–2225.

10 Albertine KH, Soulier MF, Wang Z, *et al.* Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. *Am J Pathol* 2002; 161: 1783–1796.

11 Hagimoto N, Kuwano K, Miyazaki H, *et al.* Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. *Am J Respir Cell Mol Biol* 1997; 17: 272–278.

12 Matute-Bello G, Winn RK, Jonas M, *et al.* Fas (CD95) induces alveolar epithelial cell apoptosis *in vivo*: implications for acute pulmonary inflammation. *Am J Pathol* 2001; 158: 153–161.

13 Matute-Bello G, Winn RK, Martin TR, *et al.* Sustained lipopolysaccharide-induced lung inflammation in mice is attenuated by functional deficiency of the Fas/Fas ligand system. *Clin Diagn Lab Immunol* 2004; 11: 358–361.

14 Chong ZZ, Kang JQ, Maiese K. Erythropoietin: cytoprotection in vascular and neuronal cells. *Curr Drug Targets Cardiovasc Haematol Disord* 2003; 3: 141–154.

15 Silva M, Benito A, Sanz C, *et al.* Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. *J Biol Chem* 1999; 274: 22165–22169.

16 Kashii Y, Uchida M, Kirito K, *et al.* A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction. *Blood* 2000; 96: 941–949.

17 Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. *JAMA* 2005; 293: 90–95.

18 Gray TE, Guzman K, Davis CW, *et al.* Mucociliary differentiation of serially passaged normal human tracheobronchial epithelial cells. *Am J Respir Cell Mol Biol* 1996; 14: 104–112.

19 Hamann KJ, Dorscheid DR, Ko FD, *et al.* Expression of Fas (CD95) and FasL (CD95L) in human airway epithelium. *Am J Respir Cell Mol Biol* 1998; 19: 537–542.

20 Bonfoco E, Krainc D, Ankarcrona M, *et al.* Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with *N*-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. *Proc Natl Acad Sci USA* 1995; 92: 7162–7166.

21 Terui Y, Furukawa Y, Kikuchi J, *et al.* Apoptosis during HL-60 cell differentiation is closely related to a G0/G1 cell cycle arrest. *J Cell Physiol* 1995; 164: 74–84.

22 Dorscheid DR, Wojcik KR, Sun S, *et al.* Apoptosis of airway epithelial cells induced by corticosteroids. *Am J Respir Crit Care Med* 2001; 164: 1939–1947.

23 Patchell BJ, Wojcik KR, Yang TL, *et al.* Glycosylation and annexin II cell surface translocation mediate airway epithelial wound repair. *Am J Physiol Lung Cell Mol Physiol* 2007; 293: L354–L363.

24 Davani EY, Dorscheid DR, Lee CH, *et al.* Novel regulatory mechanism of cardiomyocyte contractility involving ICAM-1 and the cytoskeleton. *Am J Physiol Heart Circ Physiol* 2004; 287: H1013–H1022.

25 Lester RD, Jo M, Campana WM, *et al.* Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. *J Biol Chem* 2005; 280: 39273–39277.

26 Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. *Chest* 2007; 131: 913–920.

27 Dagnon K, Pacary E, Commo F, *et al.* Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. *Clin Cancer Res* 2005; 11: 993–999.

28 Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. *Early Hum Dev* 1998; 52: 235–249.

29 Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med* 2005; 352: 1011–1023.

30 Frede S, Fandrey J, Pagel H, *et al.* Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1β injections in rats. *Am J Physiol* 1997; 273: R1067–R1071.

31 La Ferla K, Reimann C, Jelkmann W, *et al.* Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-κB. *FASEB J* 2002; 16: 1811–1813.

32 Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. *J Interferon Cytokine Res* 1998; 18: 555–559.

33 Grasso G, Sfacteria A, Passalacqua M, *et al.* Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin. *Neurosurgery* 2005; 56: 821–827.

34 Hashimoto S, Kobayashi A, Kooguchi K, *et al.* Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2000; 161: 237–243.

35 Matute-Bello G, Liles WC, Frevert CW, *et al.* Recombinant human Fas ligand induces alveolar epithelial cell apoptosis and lung injury in rabbits. *Am J Physiol Lung Cell Mol Physiol* 2001; 281: L328–L335.

36 Nakamura M, Matute-Bello G, Liles WC, *et al.* Differential response of human lung epithelial cells to fas-induced apoptosis. *Am J Pathol* 2004; 164: 1949–1958.

37 Tang PS, Tsang ME, Lodyga M, *et al.* Lipopolysaccharide accelerates caspase-independent but cathepsin B-dependent death of human lung epithelial cells. *J Cell Physiol* 2006; 209: 457–467.

38 Neff SB, Z'Graggen BR, Neff TA, *et al.* Inflammatory response of tracheobronchial epithelial cells to endotoxin. *Am J Physiol Lung Cell Mol Physiol* 2006; 290: L86–L96.

39 Yang S, Lin H, Diehl AM. Fatty liver vulnerability to endotoxin-induced damage despite NF-κB induction and inhibited caspase 3 activation. *Am J Physiol Gastrointest Liver Physiol* 2001; 281: G382–G392.

40 Scaffidi C, Fulda S, Srinivasan A, *et al.* Two CD95 (APO-1/Fas) signaling pathways. *EMBO J* 1998; 17: 1675–1687.

41 Breckenridge DG, Xue D. Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. *Curr Opin Cell Biol* 2004; 16: 647–652.

42 Zhande R, Karsan A. Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-κB-independent upregulation of Bcl-xL. *Am J Physiol Heart Circ Physiol* 2007; 292: H2467–H2474.

43 Johnson DW, Pat B, Vesey DA, *et al.* Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. *Kidney Int* 2006; 69: 1806–1813.

44 Kumral A, Genc S, Ozer E, *et al.* Erythropoietin downregulates bax and DP5 proapoptotic gene expression in neonatal hypoxic-ischemic brain injury. *Biol Neonate* 2006; 89: 205–210.

45 Walker DC, Behzad AR, Chu F. Neutrophil migration through preexisting holes in the basal laminae of alveolar capillaries and epithelium during streptococcal pneumonia. *Microvasc Res* 1995; 50: 397–416.

46 Jones HA, Clark RJ, Rhodes CG, *et al.* *In vivo* measurement of neutrophil activity in experimental lung inflammation. *Am J Respir Crit Care Med* 1994; 149: 1635–1639.

47 Serrao KL, Fortenberry JD, Owens ML, *et al.* Neutrophils induce apoptosis of lung epithelial cells *via* release of soluble Fas ligand. *Am J Physiol Lung Cell Mol Physiol* 2001; 280: L298–L305.

48 Suzuki T, Moraes TJ, Vachon E, *et al.* Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells. *Am J Respir Cell Mol Biol* 2005; 33: 231–247.

49 Silva M, Grillot D, Benito A, *et al.* Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. *Blood* 1996; 88: 1576–1582.

50 Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. *Br J Pharmacol* 2003; 138: 1107–1118.

51 Krafte-Jacobs B, Levetown ML, Bray GL, *et al.* Erythropoietin response to critical illness. *Crit Care Med* 1994; 22: 821–826.

52 Elliot JM, Virankabutra T, Jones S, *et al.* Erythropoietin mimics the acute phase response in critical illness. *Crit Care* 2003; 7: R35–R40.

53 Rogiers P, Zhang H, Leeman M, *et al.* Erythropoietin response is blunted in critically ill patients. *Intensive Care Med* 1997; 23: 159–162.

54 Corwin HL, Gettinger A, Fabian TC, *et al.* Efficacy and safety of epoetin-α in critically ill patients. *N Engl J Med* 2007; 357: 965–976.

55 Fischer U, Schulze-Osthoff K. Apoptosis-based therapies and drug targets. *Cell Death Differ* 2005; 12: Suppl. 1, 942–961.

56 Bohlius J, Wilson J, Seidenfeld J, *et al.* Erythropoietin or darbepoetin for patients with cancer. *Cochrane Database Syst Rev* 2006; 3: CD003407.

57 Lai SY, Grandis JR. Understanding the presence and function of erythropoietin receptors on cancer cells. *J Clin Oncol* 2006; 24: 4675–4676.

58 Ehrenreich H, Hasselblatt M, Dembowski C, *et al.* Erythropoietin therapy for acute stroke is both safe and beneficial. *Mol Med* 2002; 8: 495–505.

59 Lipsic E, van der Meer P, Voors AA, *et al.* A single bolus of a long-acting erythropoietin analogue darbepoetin-α in patients with acute myocardial infarction: a randomized feasibility and safety study. *Cardiovasc Drugs Ther* 2006; 20: 135–141.